Please login to the form below

Not currently logged in
Email:
Password:

Gilotrif

This page shows the latest Gilotrif news and features for those working in and with pharma, biotech and healthcare.

EMA starts firming up its stance on personalised medicines

EMA starts firming up its stance on personalised medicines

As more treatments like Pfizer’s Xalkori, Vertex’s Kalydeco and Boehringer Ingelheim’s Giotrif/Gilotrif come to market it also wants to better define those patients that will benefit from

Latest news

  • Boehringer stops Gilotrif head and neck cancer trials Boehringer stops Gilotrif head and neck cancer trials

    Boehringer Ingelheim has said it will abandon two trials of Gilotrif in head and neck cancer after disappointing data. ... Gilotrif (afatinib) has been on the market for EGFR-positive non-small cell lung cancer (NSCLC) for some time, and was recently

  • FDA approves expanded indication for Gilotrif FDA approves expanded indication for Gilotrif

    Boehringer Ingelheim has won US licensing for the expanded use of its EGFR-directed non-small cell lung cancer (NSCLC) drug Gilotrif. ... It showed Gilotrif achieved its primary objective of significantly improving progression-free survival when compared

  • Boehringer launches iPhone app for patients on Gilotrif Boehringer launches iPhone app for patients on Gilotrif

    More unusually though it also includes branded information about Gilotrif and on what to expect during treatment with the drug. ... Boehringer said at the time that it planned to support the Gilotrif's launch with a “comprehensive patient support

  • Opdivo gains new US lung cancer licence Opdivo gains new US lung cancer licence

    Current marketed therapies for NSCLC includes AstraZeneca's Iressa (gefitinib), Roche's Avastin (bevacizumab), as well as more recent treatments such as Pfizer's Xalkori (crizotinib) and Boehringer's Gilotrif (afatinib).

  • Boehringer’s Vargatef approved in the EU for lung cancer Boehringer’s Vargatef approved in the EU for lung cancer

    cancer.”. The launch of Giotrif/Gilotrif in 2013 as a treatment lung cancer patients who express epidermal growth factor receptor (EGFR) marked Boehringer's entry onto the oncology market.

More from news
Approximately 6 fully matching, plus 12 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics